QUOD Biobank at the British Transplant Games 2026: celebrating life, donation, and community

The 2026 British Transplant Games came to Sheffield from 6–9 August 2026, bringing together transplant recipients, living donors, donor families, supporters, and volunteers for four extraordinary days of sport, celebration, and remembrance.

For QUOD Biobank, the Games provided a particularly meaningful opportunity to celebrate the people at the heart of transplantation and to recognise the generosity of organ donors and their families.

A record-breaking Games

The 2026 Games were the largest British Transplant Games to date, with 2,857 people registered to take part. This included 1,124 transplant and stem-cell recipients competing across 26 sports, alongside 219 living donors and more than 1,500 supporters. Around 200 volunteers and 52 volunteer therapists also helped make the event possible.

Across Sheffield, competitors took part in events ranging from athletics, swimming, and cycling to golf, snooker, and team sports. The Games are about much more than sporting achievement; they demonstrate the remarkable lives that transplant recipients can lead and provide a unique opportunity for people with shared experiences to come together.

As Karen Rockell, a liver transplant recipient and member of the QUOD Biobank Steering Committee, and chair of the QUOD Lay Advisory Group (QLAG) reflected following the 2026 Games, “the sense of camaraderie and support is difficult to describe. The Games bring together people who understand the highs and lows of the transplant journey, while also providing an opportunity to meet donor families and together celebrate the gift of life.”

It was also brilliant to meet up with fellow QLAG members Andy Prigg, a double transplant recipient representing the Birmingham Transplant Team, and Mahmud Nawaz, Chair of Sheffield Teaching Hospitals NHS, member of the Donor Family Network, and NHSBT Organ Donation Ambassador.

Mahmud Nawaz, Karen Rockell, and Andy Prigg at the 2026 British Transplant Games in Sheffield
Remembering donors

One of the most moving elements of the Games is the Donor Run. Held in Sheffield city centre on Saturday 8 August, the event brought together transplant recipients, donor families, living donors, and members of the public to raise awareness of organ and stem-cell donation and to honour those whose generosity has given others a second chance at life.

More than 2,500 people took part, filling Barker’s Pool with an atmosphere of energy, celebration, and remembrance.

The significance of the event was brought into sharp focus when Liz Phillips and her daughter Jade met Steve Whelan, the recipient of Liz’s late husband Rick’s liver. Rick died suddenly in 2020, and Steve’s transplant had given him the opportunity to continue living his life. The three walked the Donor Run together in tribute to Rick.

Stories such as this capture what makes the Transplant Games so special. Behind every transplant is a human story: of generosity, loss, hope, recovery, and, ultimately, life.

QUOD Biobank joins the celebration

Although QUOD Biobank’s work is focused on research rather than sporting achievement, the connection to the Games is profound. QUOD Biobank exists because donor families generously consent or authorise the use of samples from organ donors for research. These samples, paired with rich clinical data, are made available to researchers to help improve our understanding of transplantation and, ultimately, benefit future patients.

The Games therefore provide an important reminder of why this research matters. Every sample collected through QUOD Biobank represents an opportunity to learn more about human organs, transplantation, and disease, with the potential to improve outcomes for future recipients.

Furthermore, the samples are increasingly being used in other research fields including diabetes and cardiac disease broadening the benefit to future patients.

Celebrating what is possible after transplant

The British Transplant Games send a powerful message: transplantation is not simply about survival. It can enable people to return to active, fulfilling lives and achieve things they may once have thought impossible.

The achievements of the athletes in Sheffield, whether competing for medals, taking part for the first time, or simply crossing the finish line, are a celebration of that second chance.

For everyone involved in QUOD Biobank, the Games were also a reminder of the wider community that makes transplantation possible. From donors and their families to Specialist Nurses in Organ Donation, retrieval teams, clinicians, researchers, and transplant recipients, progress in transplantation depends on people working together.

As QUOD Biobank continues to support research, we are proud to celebrate the generosity, resilience, and determination represented by the British Transplant Games.

A huge congratulations to all the athletes and our heartfelt thanks to the donors, donor families, volunteers, and everyone who made the 2026 Games such a memorable event.

Sheffield 2026 showed us, once again, that the gift of life is something to celebrate. We are looking forward to Birmingham holding the games in 2027.

Research Highlight: Hidden fibrin in donor organs linked to transplant outcomes

A new study published by Prof Chris Watson and colleagues in Transplant International investigated how commonly occult, or “hidden”, fibrin occurs in deceased donor kidneys and livers, where it may originate, and whether its presence is associated with transplant outcomes.

Fibrin is a protein involved in blood clot formation. Small fibrin deposits, known as microthrombi, have previously been observed in donor organs; however, their prevalence and clinical significance remain uncertain. The study measured levels of D-dimers, which are breakdown products released when fibrin is degraded, in fluid collected during machine perfusion of kidneys and livers from the Consortium for Organ Preservation in Europe (COPE) studies.

The results showed that occult fibrin was common in both kidneys and livers, although the amount varied considerably between organs.

In kidneys donated after circulatory death (DCD) in the COPE COMPARE study, D-dimer concentrations increased substantially during hypothermic machine perfusion, from a median of 91 ng/mL after 15 minutes to 878 ng/mL at the end of perfusion, likely due to the breakdown of existing fibrin microthrombi. Importantly, kidneys that subsequently developed delayed graft function requiring multiple dialysis sessions had significantly higher D-dimer concentrations than kidneys whose recipients did not require dialysis. However, D-dimer levels were not significantly associated with 12-month kidney function or overall graft survival. Oxygenating the perfusion fluid also did not appear to affect D-dimer concentrations.

The findings in liver were particularly noteworthy. Among 95 machine-perfused livers, 91 were subsequently transplanted. When these were divided into groups according to their D-dimer concentrations, transplant failure (defined as graft loss or recipient death) was significantly more likely over two years among livers with the highest D-dimer levels.

The study also investigated where the fibrin might originate. There were no significant differences between organs from donors who died following stroke, trauma, or hypoxia. However, organs from donors who died following euthanasia had substantially lower D-dimer concentrations. This variation according to cause of death supports the possibility that at least some of the fibrin is already present within organs before retrieval, rather than developing solely during preservation.

Pre-retrieval blood samples from 78 QUOD Biobank donors were also analysed to explore the relationship between circulating D-dimers in donors and D-dimers subsequently released from their livers during normothermic machine perfusion.

Overall, the findings suggest that occult fibrin is a common feature of deceased donor organs and may have significant consequences for early kidney function and liver transplant outcomes. This raises the possibility that identifying and potentially removing fibrin during organ preservation could become an avenue for improving transplant outcomes, although further studies are needed.

Read the full article: Evaluation of the Prevalence of Occult Fibrin in Donor Organs, Its Origins, and Consequences: Insights From the COPE Studies

The INTEGRITY Guidelines

Ethical guidance for research that involves organ and tissue donation after death: The INTEGRITY Project

What are the INTEGRITY Guidelines?

Increasing numbers of researchers want to study donation and transplantation using donated organs or tissue so they can help more people and improve the results of treatment. Until now, there has been almost no ethical guidance for this kind of research. This article describes the first international guidelines created to fill that gap, known as the INTEGRITY Guidelines.

Why these guidelines were needed

There is already clear ethical guidance for donating organs after death for a transplant, and for research that involves living people. There has been very little guidance, though, for research that involves people who may donate around the end of their life, or people who receive a transplant from someone who has died. This is a complex area. Research may involve medical steps in a person’s body before or after death, and donated materials or information may be studied years later. Without agreed standards, researchers and healthcare staff have found it hard to plan and carry out this research safely. This uncertainty can put people at risk of harm and can also hold back valuable research.

Increasing numbers of researchers want to study donation and transplantation using donated organs or tissue so they can help more people and improve the results of treatment. Donated tissues and organs that can’t be used in transplantation can also be used in valuable research investigating a range of diseases or potential treatments for non-transplant diseases, such as heart disease and diabetes.

How the guidelines were developed

Three international organisations led this work: the European Society for Organ Transplantation, the International Society for Organ Donation Professionals, and The Transplantation Society. Together they brought in a team of experts from many countries and backgrounds, including law, ethics, clinical care, and people with personal experience of transplantation. The team developed the guidelines over twelve months in four main stages:

  • First, they reviewed the existing research and identified the main ethical concerns.

  • Next, they wrote and revised draft guidelines, with feedback from a wider group of collaborators.

  • Then they invited the public to comment.

  • Finally, they reviewed the comments and agreed on a final version.

The team held workshops in Australia, the United Kingdom and Japan during this period. The three organisations formally approved the final guidelines in April 2026.

What people said during the public consultation

The team asked for public feedback through an online survey, which people could complete in eight languages. A total of 271 people from 48 countries gave complete responses. They came from many different backgrounds, and just over half were healthcare professionals. People could say how much they agreed with each proposed principle and add their own comments. Every proposed principle received agreement from at least three out of four people, and most received agreement from at least nine out of ten. This showed strong support for the approach taken.

What the guidelines cover

The guidelines are designed to help researchers, healthcare staff, people taking part in research, families making decisions, and the committees that review research. They apply to research involving adults and children, including people who are not able to make decisions for themselves. They cover a wide range of research, such as:

  • Medical steps in the body of a person who has died.

  • Collecting or using personal information about a donor.

  • Studying donated organs, cells or tissues, including before a transplant or after it.

  • Listening to the experiences of donor families, transplant recipients, or healthcare staff.

  • Using information first collected for care or record-keeping in later research.
The eight core principles

The guidelines are built around eight core principles. In plain terms, they ask that:

  1. Dignity is respected
    Research should always treat people who have died, and their bodies, with respect and care. Donating for research should be valued as a meaningful gift, much like donating for a transplant.

  2. Chances are fair
    Everyone should have a fair opportunity to take part in research and to share in what it discovers. No group should be left out or unfairly singled out.

  3. Everyone affected is considered
    Researchers should think about all the people a study might affect, including the donor, their family, people waiting for a transplant, and healthcare staff.

  4. Transplants come first
    Research should not unfairly reduce the organs, cells and tissues available for transplants. If there is a clash, making sure people who need a transplant can receive one usually takes priority.

  5. Privacy is protected
    Personal information about donors, families, transplant recipients and staff should be kept private and confidential.

  6. Research is open and honest
    Research should be carried out openly so that people can trust it, results should be shared, and any concerns should be open to review.

  7. People’s choices are respected
    People, or their families speaking for them, should be supported to make informed choices about taking part. A person’s right to make their own decisions is called autonomy. When others decide on behalf of someone who cannot decide, they should follow what that person would have wanted.

  8. The body is never bought or sold
    The human body and its parts must never be traded. Donors and their families should neither lose nor gain money because of donation, although necessary costs can be covered.
What the guidelines do not do

These guidelines set out principles rather than step-by-step instructions. Each country will need to adapt them to fit its own laws and existing rules, and to use them alongside the usual guidance for research and for donation. The team also notes an important limit: members of the public, donor families and transplant recipients took part in smaller numbers than other groups. Future versions should include a wider range of voices.

What happens next

In 2024, the World Health Assembly called on member states to promote research and innovation to maximize the use and optimize the outcomes of transplantation of human cells, tissues and organs, as well as enable development of alternative therapies to those based on the clinical use of human cells, tissues and organs. These first international guidelines offer a strong starting point, but more work is needed to put them into practice, including training for those who use them. There are plans for further guidance on specific topics, such as consent, sharing of records, and the role of companies in research. In some countries change in culture may also help, so that research is seen as another option to offer donors and recipients, rather than something that competes with their care. Working together early can help include research in organ donation while keeping care for donors, their families and recipients at a very high standard.

The INTEGRITY Guidelines are now available in Transplant International.

Spotlight on a QUOD Colleague: Ana Gil-Bernabe

Behind every successful biobank is a framework of policies, procedures, and safeguards that ensures precious donated samples are handled responsibly and research can take place according to the required legislation. This issue’s QUOD Spotlight Interview introduces Ana Gil-Bernabe, Quality and Governance Manager for QUOD Biobank, whose hard work helps keep everything running smoothly behind the scenes.

Ana’s role involves making sure that everything is done correctly, ensuring that QUOD Biobank’s activities comply with three levels of regulation: national legislation; University of Oxford policies; and the biobank’s own local procedures. These include requirements set by the Human Tissue Authority (HTA), the Health Research Authority, and relevant legislation, alongside university policies covering human tissue, information security, data handling, and laboratory practices.

Ana makes sure that everyone has the right procedures and training in place to carry out their work correctly and consistently. Standardisation is central to this. Clear, regularly reviewed procedures help ensure that samples are collected, processed, stored, and distributed consistently across QUOD Biobank’s network, supporting both regulatory compliance and reliable research. QUOD Biobank operates through a central team in Oxford and a network of regional centres across the UK. Each team member requires training and documentation relevant to their responsibilities. Ana manages this through iPassport, QUOD Biobank’s quality management system, which provides access to standard operating procedures, tracks training, and records competency. Documents are formally reviewed every two years, or earlier, when necessary, while training and compliance are monitored more regularly.

For Ana, quality management and governance are much more than checking boxes; they are about learning and improving. Regular meetings provide opportunities to discuss incidents, near misses, and potential improvements. These conversations encourage an open culture where staff feel comfortable asking questions and raising concerns. “People are very respectful of the procedures and aren’t afraid to ask before doing something they’re unsure about,” she says.

QUOD Biobank also carries out regular audits to ensure satisfaction of the four core HTA standards: consent; premises and equipment; traceability; and quality management. Ana sees these reviews as opportunities to improve rather than simply demonstrate compliance. “As the biobank matures, we need to keep questioning why we do things in a particular way and whether there might be a better approach.” She works closely with the University of Oxford’s Human Tissue Governance group, which supports compliance with the institutional HTA licence and provides guidance when complex questions arise.

Ana is particularly keen to challenge the perception that governance is simply about restrictions and paperwork. Regulations exist to protect donors, ensure samples are handled respectfully, and maintain confidence in research. Although agreements and approvals can take time, these safeguards are essential. “Governance is a pathway to research activity, as it allows you to do the things you perhaps thought you might not be able to do.”

Having previously worked as a researcher herself, Ana understands the importance of enabling scientists to access the materials they need. She loves engaging with research in her job and says “it is our job to facilitate research but to respect the regulations.”

Ana’s career path to her role in governance evolved with her.  She has always been fascinated by the human body and the science behind how it works. In Spain, where Ana grew up, she studied Pharmacy at the University of Santiago de Compostela, before completing a PhD in Oncology at the University of Seville. A research placement in Vienna during her PhD confirmed her enthusiasm for scientific discovery, and she subsequently moved to Oxford for a postdoctoral position to study cancer metastasis. However, balancing the demands of laboratory research with family life became increasingly challenging after the birth of her daughter, with her husband also working as a postdoctoral researcher. When an opportunity arose to move into a governance role within Oxford’s Department of Oncology, Ana recognised that it offered a way to remain involved in science while achieving a better balance. The transition proved a natural fit, combining her understanding of laboratory research with the legal, ethical, and practical requirements of research governance. Although she no longer works directly at the laboratory bench, she finds great satisfaction in helping others carry out their research.

Outside of work, Ana’s greatest passion is the sea. Having grown up on the Spanish coast, she misses having the water on her doorstep now that she lives in Oxford. She recently discovered the word thalassophilia, meaning a deep love of the sea, and immediately recognised herself in it. Ana loves several water sports, from swimming to sailing, snorkelling, and diving, and says that being near the water brings her a sense of peace and happiness as well as a connection with nature. Her love of travelling and spending time with family saw Ana go diving at the Great Barrier Reef while visiting her Australian husband’s family, which was a real highlight for her. For someone whose work involves navigating complex regulations and ensuring that everything runs smoothly, perhaps it’s fitting that Ana finds her greatest sense of calm beneath the waves.